Bioavailability of bromazepam in man after single administration of an oral solution.
The relative bioavailability of a liquid oral form of 7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one (bromazepam, Lexotan, Lexotanil) in comparison with the conventional oral form (capsules) was investigated. The study was performed on six healthy volunteers who were administered both the drug products in a single oral dose of 3 mg of bromazepam in a randomized cross-over trial. An additional investigation was performed on the same subjects by administering the liquid oral solution at a lower dosage: 1.5 mg in order to confirm first-order kinetics at low dosage, too. The results showed the same bioavailability for the oral forms tested and confirmed first-order kinetics for the 1.5 mg dose, too.
D000284:Administration, Oral; D000328:Adult; D014151:Anti-Anxiety Agents / Q000378:metabolism*; D001682:Biological Availability; D001960:Bromazepam / Q000378:metabolism*; D002214:Capsules; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D012996:Solutions
D014151:Anti-Anxiety Agents; D002214:Capsules; D012996:Solutions; D001960:Bromazepam